Dr. Randi Hagerman
- Home
- Dr. Randi Hagerman
Distinguished Professor of Pediatrics & Endowed Chair in Fragile X Research, UC Davis MIND Institute
Dr. Randi Hagerman
Dr. Randi Hagerman is a developmental and behavioral pediatrician and Distinguished Professor of Pediatrics at the UC Davis MIND Institute, where she holds an Endowed Chair in Fragile X Research. She is internationally recognized as a clinician and researcher in neurodevelopmental disorders, including autism and fragile X syndrome.
Dr. Hagerman earned her M.D. from Stanford University, where she also completed her pediatric residency. She completed a fellowship in Learning and Disabilities and Ambulatory Pediatrics at UC San Diego, then led the Division of Developmental and Behavioral Pediatrics at the University of Colorado for 20 years.
She co-founded the National Fragile X Foundation in 1984. In 2000, she joined the MIND Institute, conducting treatment trials for ASD, fragile X syndrome, and premutation disorders. There, she and her husband and research team discovered Fragile X–associated Tremor/Ataxia Syndrome (FXTAS), a neurodegenerative disorder associated with the fragile X premutation.
Dr. Hagerman has authored over 500 peer-reviewed articles and book chapters, and edited major works including Fragile X Syndrome and Premutation Disorders (2020) and the second edition of the Textbook of Autism Spectrum Disorders (2023). She has received numerous awards, including the Lifetime Achievement Award from the NFXF and the C. Anderson Aldrich Award for Outstanding Career Achievement from the AAP.
Professional Highlights :
Peer-Reviewed Articles & Book Chapters
National Fragile X Foundation
Co-Discovered Fragile X–Associated Tremor/Ataxia Syndrome
Dr. Randi Hagerman Talk
Fragile X Spectrum Disorders and New Treatments
Abstract
Dr. Hagerman will discuss the fragile X gene mutations, which occur in full and premutation forms and are associated with a spectrum of neurodevelopmental and neurodegenerative conditions. She will highlight clinical manifestations in males and females, including intellectual disability, autism, and emotional/learning challenges, as well as adult-onset conditions such as FXPOI and FXTAS.
Spectrum: Explains the full mutation vs premutation and associated neurodevelopmental and neurodegenerative disorders.
Clinical Manifestations: Discusses cognitive, behavioral, and emotional features across ages and sexes.
Targeted Treatments: Reviews current and emerging therapies, including metformin and phosphodiesterase 4D inhibitors, aimed at improving cognition, behavior, and overall outcomes in fragile X syndrome.
Translational Research: Emphasizes bridging molecular discoveries with practical clinical interventions for patients and families.
Are You Ready?
Join a global community shaping the future of neurodevelopmental research, care, and advocacy.